Researchers & Healthcare Professionals

www.lls.org/researchershealthcareprofessionals

Did you know?

LLS Therapy Acceleration Program partner, Celator, has completed their targeted enrollment of 120 first relapsed AML patients for their phase II trial of their liposomal drug CPX-351.

Blood Cancer Treatment - Making Informed Choices

Note: The free Adobe Acrobat Reader® is required to view and print Adobe PDF files, and the free Windows Media Player or RealPlayer is required to listen to the MP3 audio files.

Date: February 26, 2013
Time: 1:00 p.m. - 2:00 p.m. ET
Location: Telephone/Web
Target Audience: Oncology nurses and social workers involved in the treatment of patients with blood cancer
Read: Program Slides | Transcript
Listen: Presentation | Q&A Session

Virtual lecture will be available soon.

Activity Purpose

To educate oncology nurses and social workers about treatment options for blood cancer.

Educational Objectives

At the conclusion of this program, participants should be able to:

  • Explain the goals of treatment for a patient's particular diagnosis
  • Describe what patients need to know about their treatment options
  • List benefits and risks for both standard and investigational treatments
  • List key facts about clinical trials

Speaker

Stephen D. Nimer, MD
Director
Sylvester Comprehensive Cancer Center
Professor of Medicine, Biochemistry & Molecular Biology
University of Miami Miller School of Medicine
Miami, FL

Sponsors and Supporters

This program is sponsored by The Leukemia & Lymphoma Society and supported by grants from Celgene Corporation and Millennium: The Takeda Oncology Company.

last updated on Wednesday, April 17, 2013
btn_sharethis